AstraZeneca Partners With Insitro in $1.86 Billion AI Deal
AstraZeneca entered a collaboration with Insitro to use machine learning for discovering new treatments for heart muscle and fatty liver diseases.
AstraZeneca Plc entered a collaboration agreement with machine learning biotech firm Insitro Inc. to discover new medicines for heart muscle diseases and fatty liver conditions. The deal is valued at up to $1.86 billion, starting with an upfront payment of $40 million from the British drugmaker.
Insitro will combine its own data with AstraZeneca's data to identify the underlying causes of these conditions. If the partnership achieves its specific goals, Insitro is eligible for additional payments totaling as much as $1.46 billion, as well as potential royalties on future sales of the resulting medicines.
